Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -83.89% is 87% above its 5-year average of -645.79%, near the high end of its 5-year range (-49519.23%–14.42%).
76.56% above its 12-month average of -357.83%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1112.85%.
EBITDA MARGIN
-83.89%
EBITDA MARGIN AVG TTM
-357.83%
EBITDA MARGIN AVG 3Y
-490.51%
EBITDA MARGIN AVG 5Y
-645.79%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+76.56%
CURRENT VS 3Y AVG
+82.90%
CURRENT VS 5Y AVG
+87.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cue Biopharma, Inc.
Market Cap
$166.66M
EBITDA Margin
-83.89%
TTM Avg
-357.83%
3Y Avg
-490.51%
5Y Avg
-645.79%
Market Cap
$168.66M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
Market Cap
$169.21M
EBITDA Margin
14.71%
TTM Avg
8.99%
3Y Avg
8.81%
5Y Avg
10.76%
Market Cap
$165.17M
EBITDA Margin
14.98%
TTM Avg
2.40%
3Y Avg
-11.30%
5Y Avg
-6.96%
Market Cap
$164.91M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
Market Cap
$170.85M
EBITDA Margin
-144.16%
TTM Avg
-87.79%
3Y Avg
-115.19%
5Y Avg
-149.65%
Market Cap
$162.44M
EBITDA Margin
-65.55%
TTM Avg
-49.11%
3Y Avg
-55.76%
5Y Avg
-50.22%
Market Cap
$170.91M
EBITDA Margin
-6.19%
TTM Avg
-12.15%
3Y Avg
-13.37%
5Y Avg
-13.97%
Market Cap
$161.45M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | $166.66M | -83.89% | -357.83% | -490.51% | -645.79% |
| MediWound Ltd. (MDWD)vs › | $168.66M | -138.09% | -113.30% | -81.67% | -67.39% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | 14.71% | 8.99% | 8.81% | 10.76% |
| OptimizeRx Corp. (OPRX)vs › | $165.17M | 14.98% | 2.40% | -11.30% | -6.96% |
| Nkarta, Inc. (NKTX)vs › | $164.91M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| Precision BioSciences, Inc. (DTIL)vs › | $170.85M | -144.16% | -87.79% | -115.19% | -149.65% |
| Quanterix Corporation (QTRX)vs › | $162.44M | -65.55% | -49.11% | -55.76% | -50.22% |
| Journey Medical Corporation (DERM)vs › | $170.91M | -6.19% | -12.15% | -13.37% | -13.97% |
| Coherus Oncology, Inc. (CHRS)vs › | $161.45M | -416.41% | -228.13% | -163.44% | -116.60% |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.50M | 4.91% | 4.91% | 4.91% | 4.91% |
Gross Margin
99.7%
EBITDA Margin
-83.9%
Operating Margin
-96.6%
Net Margin
-435.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1112.85% |
| 2026-03-31 | -77.98% |
| 2025-12-31 | 14.42% |
| 2025-09-30 | -347.37% |
| 2025-06-30 | -265.37% |
| 2025-03-31 | -2711.88% |
| 2024-12-31 | -605.01% |
| 2024-09-30 | -237.95% |
| 2024-06-30 | -358.05% |
| 2024-03-31 | -688.35% |
| 2023-12-31 | -753.38% |
| 2023-09-30 | -537.57% |
| 2023-06-30 | -916.64% |
| 2023-03-31 | -6684.49% |
| 2022-12-31 | -9710.60% |
| 2022-09-30 | -15926.47% |
| 2022-06-30 | -49519.23% |
| 2022-03-31 | -1393.50% |
| 2021-12-31 | -91.87% |
| 2021-09-30 | -530.35% |
| 2021-06-30 | -364.70% |
| 2021-03-31 | -785.58% |
| 2020-12-31 | -2255.54% |
| 2020-09-30 | -1400.85% |
| 2020-06-30 | -992.56% |
| 2020-03-31 | -1414.67% |
| 2019-12-31 | -839.53% |
| 2019-09-30 | -701.12% |
| 2019-06-30 | -759.62% |
| 2019-03-31 | -2762.43% |
| 2018-12-31 | -3255.45% |
| 2018-09-30 | -2798.44% |
| 2018-06-30 | -4230.81% |
